genocea biosciences

Three Highly Unusual Volume Increases: Genocea Biosciences Inc (NASDAQ:GNCA …
www.wallstreetpoint.com

The Healthcare Company on October 7, 2015statedpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its …

8
Like
Save
Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ContraVir …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

5
Like
Save
Mid-Day ETF Update: ETFs, Stocks Struggle to Stay Higher as Oil Prices Fall on …
www.nasdaq.com

Genocea Biosciences (GNCA) rose 8.6% after reporting that interim analysis of Phase 2 data on its GEN-003 genital herpes vaccine demonstrated a statistically significant 58% reduction in the viral shedding rate, the primary endpoint of the study.

6
Like
Save
Biotech Stocks with Active Concerns: Genocea Biosciences, Inc. (NASDAQ:GNCA …
www.senecaglobe.com

… cell-directed vaccines and immunotherapies, recently reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of …

3
Like
Save
Premarket Biotech Digest: Evoke Pharma Rallies, Avelumab Fast Tracked, Vertex …
seekingalpha.com

… Phase II Trial of GEN-003 – Genocea Biosciences (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its Phase II dose optimization trial of GEN-003 for the treatment of genital herpes.

2
Like
Save
Genocea Bio's GEN-003 achieves primary endpoint in mid-stage genital herpes …
seekingalpha.com

An interim analysis of six-month data from a Phase 2 clinical trial evaluating Genocea Biosciences' (NASDAQ:GNCA) lead product candidate GEN-003 for the treatment of genital herpes showed a 58% reduction from baseline in the viral shedding rate …

7
Like
Save
Checklist Early morning Stocks: SBA Communications Corporation (NASDAQ:SBAC …
www.wsnews4investors.com

Genocea Biosciences, Inc. (GNCA reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Pre-market most advance: Genocea Biosciences (NASDAQ:GNCA), Breitburn Energy …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

3
Like
Save
Genocea Bio's GEN-003 achieves primary endpoint in mid-stage genital herpes trial
seekingalpha.com

An interim analysis of six-month data from a Phase 2 clinical trial evaluating Genocea Biosciences' (NASDAQ:GNCA) lead product candidate GEN-003 for the treatment of genital herpes showed a 58% reduction from baseline in the viral shedding rate …

9
Like
Save
Genocea Climbs on Follow-Up Data for Herpes Vaccine …
www.xconomy.com

It hasn't all been smooth sailing for Genocea Biosciences as it tries to prove the worth of a new, quick-hit vaccine technology. The company currently trad.

8
Like
Save